Carboplatin in Combination With Epirubicin and Cyclophosphamide in Patients With Advanced Ovarian Cancer: A Phase II Study

Acta Oncologica - United Kingdom
doi 10.3109/02841869509127192
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

A Phase I Trial of Dasatinib, an SRC-Family Kinase Inhibitor, in Combination With Paclitaxel and Carboplatin in Patients With Advanced or Recurrent Ovarian Cancer

Clinical Cancer Research
Cancer ResearchOncology
2012English

Gemcitabine Plus Carboplatin in Patients With Advanced Hepatocellular Carcinoma: Results of a Phase II Study

ISRN Oncology
2012English

A Pilot Study of Carboplatin (JM8, CBDCA) and Chlorambucil in Combination for Advanced Ovarian Cancer

British Journal of Cancer
Cancer ResearchOncology
1988English

A Phase II Study of Carboplatin in Advanced or Metastatic Stomach Cancer

European Journal of Cancer and Clinical Oncology
1987English

Phase II Study of Carboplatin, Vinorelbine and Capecitabine in Patients With Metastatic Breast Cancer

The Internet Journal of Oncology
2007English

Phase I, Pharmacokinetic, and Biological Study of Erlotinib in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Tumors

Clinical Cancer Research
Cancer ResearchOncology
2006English

A Phase Ib and Pharmacokinetic Trial of Patupilone Combined With Carboplatin in Patients With Advanced Cancer

Clinical Cancer Research
Cancer ResearchOncology
2007English

Neoadjuvant 5-Fluorouracil, Epirubicin and Cyclophosphamide Chemotherapy Followed by Docetaxel in Refractory Patients With Locally Advanced Breast Cancer

Oncology Reports
MedicineCancer ResearchOncology
2007English

A Phase Ib/Ii Study of HER3-targeting Lumretuzumab in Combination With Carboplatin and Paclitaxel as First-Line Treatment in Patients With Advanced or Metastatic Squamous Non-Small Cell Lung Cancer

ESMO Open
Cancer ResearchOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy